Haemonetics
275 hedge funds and large institutions have $6.28B invested in Haemonetics in 2019 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 89 increasing their positions, 97 reducing their positions, and 25 closing their positions.
80% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 25
7% more funds holding
Funds holding: 256 → 275 (+19)
2% more capital invested
Capital invested by funds: $6.15B → $6.28B (+$131M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 97
1.62% less ownership
Funds ownership: 99.67% → 98.05% (-1.6%)
26% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $16.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$144M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$41.6M |
| 3 |
Renaissance Technologies
New York
|
+$18.1M |
| 4 |
JP Morgan Chase
New York
|
+$16.8M |
| 5 |
Millennium Management
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Eminence Capital
New York
|
-$73.8M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$47.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$44.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$40.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.4M |
HAE Hedge Fund Activity: Q3 2019 in Review
275 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2019, worth a combined $6.28B — up 2.1% from $6.15B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new HAE positions and 25 closed out — a net gain of 20 holders — while 89 added to existing stakes and 97 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $144M. The largest seller was Eminence Capital, cutting an estimated $73.8M.
- 275 institutional investors held Haemonetics (HAE) as of Q3 2019, up from 256 in Q2 2019.
- Funds reported $6.28B of Haemonetics stock for Q3 2019, up 2.1% quarter-over-quarter.
- 45 funds opened new Haemonetics positions in Q3 2019 and 25 closed out, a net change of +20 holders.
- The largest Haemonetics buyer in Q3 2019 was Fidelity Investments, an estimated $144M added.
- The largest Haemonetics seller in Q3 2019 was Eminence Capital, an estimated $73.8M sold.
Based on aggregated 13F filings for Q3 2019.